

Innovative Medicines Initiative

Developing a framework for rapid assessment of vaccination benefit/risk in Europe


Vincent Bauchau (GSK Biologicals)





Need for public-private collaboration





Year




Please note the log scale Orenstein et al. 2004, Journal of Infectious Diseases 189:S1–3



Need for public-private collaboration






Data source: HPA, <u>http://www.hpa.org.uk/Topics/InfectiousDiseases/</u> InfectionsAZ/Measles/EpidemiologicalData/measDataMMRConfirmed/



Need for public-private collaboration







Need for public-private collaboration



Diversity of stakeholders: regulatory agencies, public health institutes, vaccine manufacturers, ...

Integrated, rapid system to maintain or restore public trust as fast as possible

Challenges on both a technical and governance level


- Data sources
- Analytical methods for integrated B/R
- Not enough coordination, overlap
- Transparent governance rules






Objectives of the full project







Objectives of the full project



- Long-term vision: an efficient and sustainable infrastructure for rapid and integrated post-licensure monitoring of vaccines under clear governance rules meeting the common interest of all main stakeholders
- Aim of this call: deliver the necessary steps to prepare the implementation of a sustainable system





Objectives of the full project



Objectives of this call

- Indentify/develop governance principles and rules that recognise all main stakeholders
- Map the current synergies in existing relevant ongoing projects that provide relevant data, information and methodological tools
- Proof of concept studies
- Deliver an action plan for long-term expandability and sustainability to allow transition to production









- Current needs and challenges are similar across all vaccine manufacturers
- Governance and tools will be similarly useful to all





Suggested architecture of the project



- WP1: Governance and code of conduct for public/private partnership in studies of benefit/risk of vaccines
- WP2: Mapping of project synergies
- WP3: Data sources for rapid and integrated benefit/risk analyses





Suggested architecture of the project



- W4: Identification and/or development of methods for integrated analysis of burden of diseases, vaccination coverage and vaccine safety and effectiveness
- WP5: Proof-of-concept studies of a framework to perform vaccine benefit/risk
- WP6: Project Management





Expected (in kind) contributions of EFPIA members



- Expertise in vaccines
- Experience in the challenges to implement studies defined by Risk Management Plans
- Research capacity in disease epidemiology, pharmacoepidemiology, pharmacovigilance





What's in it for you?



- Unique opportunity for all stakeholders to sit around the table
- Exciting and challenging project
- Long term vision





Key deliverables of the full project



- Annual review to map the needs, gaps, resources, methods and processes for rapid, integrated post-approval monitoring of vaccines in Europe, reflecting the views of all main stakeholders
- Proof-of-concept studies to assess selected data sources, analytical methods and governance rules
- A recognised central forum to build trust between all the main stakeholders and facilitate timely agreement on governance
- Guidance for best practices and governance for the conduct of pharmacoepidemiological studies to monitor benefit/risk of vaccines under private/public partnership
- An action plan for a sustainable framework for assessing vaccine impact, including plan for governance, funding mechanism, integration of/with other initiatives (as mapped) and supporting organisation.









Contact the IMI Executive Office E-mail: infodesk@imi.europa.eu Website: www.imi.europa.eu



